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A B S T R A C T
Purpose
This was a multinational, open-label, randomized phase III trial comparing yttrium-90–labeled
murine HMFG1 (90Y-muHMFG1) plus standard treatment versus standard treatment alone in
patients with epithelial ovarian cancer (EOC) who had attained a complete clinical remission after
cytoreductive surgery and platinum-based chemotherapy.
Patients and Methods
In total, 844 International Federation of Gynecology and Obstetrics stage Ic to IV patients were
initially screened, of whom 447 patients with a negative second-look laparoscopy (SLL) were
randomly assigned to receive either a single dose of 90Y-muHMFG1 plus standard treatment (224
patients) or standard treatment alone (223 patients). Patients in the active treatment arm received
a single intraperitoneal dose of 25 mg of 90Y-muHMFG1 (target dose 666 MBq/m2). The primary
end point was length of survival; secondary end points included time to relapse and safety. The
study had an 80% power to detect a 15% change in survival.
Results
After a median follow-up of 3.5 years (range, 1 to 6 years), 70 patients had died in the active
treatment arm compared with 61 patients in the control arm. Cox proportional hazards analysis of
survival demonstrated no difference between treatment arms. In the study drug arm, 104 patients
experienced relapse compared with 98 patients in the standard treatment arm. No difference in
time to relapse was observed between the two study arms. Active therapy was associated with
occasional grade 3 or 4 thrombocytopenia and neutropenia and grade 1 or 2 GI symptoms,
abdominal discomfort, arthralgia, and myalgia.
Conclusion
A single IP administration of 90Y-muHMFG1 to patients with EOC who had a negative SLL after
primary therapy did not extend survival or time to relapse.
J Clin Oncol 24:571-578. © 2006 by American Society of Clinical Oncology
INTRODUCTION
Epithelial ovarian cancer (EOC) is the fifth leading
cause of cancer death among women in the United
States and Northern and Western Europe.1 Despite
high response rates to cytoreductive surgery fol-
lowed by platinum-based chemotherapy, the relapse
rate is high, and consequently, for patients with ad-
vanced disease, the 5-year survival rate is approxi-
mately 25% to 35%.2,3 Because the site of disease
recurrence is usually within the peritoneal cavity,
intraperitoneal (IP) consolidation strategies offer
the possibility of focusing therapy to the site of resid-
ual disease while minimizing systemic toxicities.4,5
The HMFG1 murine monoclonal antibody is
directed at a specific epitope of the MUC1 gene
product, which is a large, heavily glycosylated mucin
expressed on the apical surface of the majority of
secretory epithelial cells.6 MUC1 is an attractive tar-
get for immunotherapy because it is overexpressed
in 90% of adenocarcinomas, including cancers of
the ovary, breast, and pancreas, and is antigenically
distinct from normal tissue mucin as a result of
underglycosylation or aberrant glycosylation of this
protein in cancerous tissue.7 The extracellular por-
tion of the MUC1 protein mainly consists of a vari-
able number of highly conserved 20 amino acid
repeats. In malignancy, the complex carbohydrate
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side chains are truncated, leading to exposure of cryptic epitopes
within these amino acid repeats.8,9
The radiolabeled monoclonal antibody HMFG1 has been previ-
ously used to successfully image lesions in patients with primary and
metastatic ovarian cancer.10 However, the absolute amount of anti-
body reaching the target was not considered to be high enough for
effective targeting of radioactivity.11 This led to the concept of apply-
ing radiolabeled antibodies regionally (ie, IP or intrapleurally) for the
treatment of regionally confined tumors such as ovarian cancer.
In a nonrandomized, extended, phase I/II trial, patients with
EOC were treated with a radiolabeled HMFG1 antibody, yttrium-90–
labeled murine HMFG1 (90Y-muHMFG1), administered once IP af-
ter surgical debulking and chemotherapy.12 The primary results of
that study13 as well as an update14 demonstrated prolonged disease-
free survival in a small cohort of patients who had received the therapy
after achieving a complete remission with conventional primary che-
motherapy. On the basis of the results of the phase I/II study, the Study
of Monoclonal Antibody Radioimmunotherapy was initiated. The
primary aim of this large phase III trial was to evaluate whether the
delivery of a single dose of IP 90Y-muHMFG1 prolonged survival.
Secondary study end points included an analysis of relapse and safety
of 90Y-muHMFG1 after surgery and platinum-based chemotherapy.
PATIENTS AND METHODS
Between February 1998 and January 2003, 844 patients were initially screened,
of whom 702 met primary eligibility criteria and were enrolled after written
informed consent was provided. The study, which involved 74 centers in 17
countries, was sponsored by Antisoma Ltd (London, United Kingdom) and
approved by the appropriate scientific and ethical authorities and was con-
ducted in compliance with Good Clinical Practice and the standards of the
Declaration of Helsinki.
Eligibility Criteria
Patients who were entered onto this randomized, open-label, phase III
study had to fulfill the following criteria: histologically proven EOC (all histol-
ogy was reviewed before random assignment by a central pathology review
committee: G. Stamp and G. Spiegel), International Federation of Gynecology
and Obstetrics (FIGO) stage Ic, and complete clinical response, as assessed
by physical examination, computed tomography (CT) scan, and CA-125. All
patients were required to have received a platinum-based chemotherapy reg-
imen and to have undergone an attempt at surgical cytoreduction. At the time
of primary screening, patients had to be 18 years old or older, have an Eastern
Cooperative Oncology Group (ECOG) performance status of 0 to 2, and a life
expectancy of more than 3 months. At baseline, patients had to have adequate
hematologic (leukocyte count 3 109/L, platelet count 100 109/L, and
hemoglobin 10 g/dL), renal (serum creatinine 177mol/L or 20 mg/L),
and liver function (ALT and AST not higher than 2 the upper limit of
normal). In addition, the final eligibility criteria included a macroscopically
negative second-look laparoscopy (SLL) that was to be performed in those
patients who met primary eligibility criteria between 4 and 8 weeks after the
delivery of their final cycle of chemotherapy.
Patients were excluded from entering the study if they had known me-
tastases at the time of the SLL or had prior/concomitant malignancy, other
than basal cell carcinoma of the skin. Patients with extensive IP adhesions that
would prevent dispersal of study medication in less than three quadrants were
excluded. This was assessed both at the time of laparoscopy and then by CT
scan or isotope diffusion scan. Patients who had previous exposure to a murine
antibody, were positive for human antimurine antibodies (HAMA) at a level of
greater than 50 ng/mL (HAMA Elisa; Roche Diagnostics, Basel, Switzerland),
or had a tumor that proved to be MUC1 negative at central pathology review
were excluded. Patients participating in other trials involving investigative
consolidation or intensification strategies were also excluded, as were patients
with recurrent disease.
Study Medication
The murine HMFG1 anti-MUC1 monoclonal antibody was manu-
factured by BioInvent (Lund, Sweden) in accordance with the standards of
Good Manufacturing Practice. The murine HMFG1 antibody is an intact
immunoglobulin G1. The investigational product comprised the following
two components: 20 mg of muHMFG1 and 5 mg of immunoconjugate
(muHMFG1 antibody linked to the chelating agent p-isothiocyanato-
benzyldiethylenetriaminepentaacetic acid), as described previously.15 Im-
mediately before administration, the immunoconjugate, muHMFG1–p-
isothiocyanatobenzyldiethylenetriaminepentaacetic acid was radiolabeled
with yttrium-90, a radioactive beta-emitting metal. Thin-layer chromatog-
raphy was conducted to ensure a minimum of 95% radiolabeling efficacy.
Study Procedures
Patients were randomly assigned (1:1) to receive either 90Y-muHMFG1
plus standard care or standard care only. After random assignment but before
administration of study medication, patients had to undergo an SLL to con-
firm the absence of macroscopic disease. Patients with visible disease at SLL
were excluded from the study. Patients without visible residual disease who
were assigned to active therapy received a single IP infusion of 90Y-muHMFG1
25 mg to provide a planned dose of 666 MBq/m2 (18 mCi/m2) of body-surface
area and not exceeding 1,110 MBq (30 mCi) in total. During the first hour after
administration of study medication, the patient was moved frequently to
ensure adequate dispersal of medication.
Institutions were permitted to deliver other standard consolidation ther-
apies after the study per written institutional guidelines, which were defined
before study initiation. In all cases, the standard consolidation therapy was
delivered to patients in both treatment groups. Institutions choosing consoli-
dation strategies that were potentially myelotoxic were not permitted to initi-
ate such therapies within 4 weeks of study medication.
Patients who received 90Y-muHMFG1 were observed weekly for the first
6 weeks and at week 8 and month 3, whereas patients who received standard
care were observed at weeks 1, 4, and 8 and month 3. Thereafter, follow-up for
all patients occurred at 3-month intervals for 36 months and then at 6-month
intervals until study completion.
Assessments conducted during the study included clinical tumor evalu-
ation, laboratory assessments (hematology, biochemistry, CA-125, and
HAMA levels), ultrasound, CT or magnetic resonance imaging scan (when
relapse was suspected and at least once per year), Eastern Cooperative Oncol-
ogy Group performance status, and assessments of adverse events.
Efficacy Parameters
The primary efficacy end point was overall survival. For patients who
died during the study, survival was measured as the number of days between
the SLL and death from any cause. Survival times for all other patients were
censored at the end of the trial (March 8, 2004) or when the patient was
withdrawn from the study, whichever occurred first.
Secondary efficacy end points included an analysis of time to relapse.
Time to relapse was defined as the time from laparoscopy to clinical presence
of disease or time of death, if death occurred without a prior diagnosis of
relapse. The clinical presence of disease had to be supported by independent
assessment, using radiologic, histologic, or cytologic evidence.
Safety Parameters
Safety was assessed by the collection of adverse events, toxicity (evalu-
ated, recorded, and graded using the National Cancer Institute Common
Toxicity Criteria), and laboratory data. Adverse events were collected for up to
3 months after the SLL; severe adverse events were collected throughout the
study. Severe adverse events were defined as any event that resulted in death,
was life threatening, required hospitalization or prolongation of existing hos-
pitalization, or resulted in persistent or significant disability/incapacity. Safety
was independently monitored on a regular basis during the study by an
independent Data and Safety Monitoring Board.
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Statistical Methods
This study had an 80% power to detect a 15% difference in survival times
between the two study arms. The study design was event driven, and patients
were observed until at least 116 deaths had occurred. All statistical tests were
performed at the 0.05 level of significance, unless specifically stated, and were
two sided. A single hypothesis test, comparing treatment groups with respect
to all-cause mortality, was confirmatory, with a difference between the treat-
ments being asserted if the observed significance level was less than 0.05. The
intent-to-treat population was the primary population. A single interim anal-
ysis evaluating primary outcomes was performed after 87 deaths and was
presented to the independent Data and Safety Monitoring Board.
Time to event variables were estimated using the Kaplan-Meier method.
Differences between treatments with respect to time to event variables were
assessed using either the log-rank test or Cox model regression when it was
necessary to consider the impact of covariates. Analysis of survival times was
performed using a Cox model regression with the inclusion of the following
two binary covariates: initial FIGO stage at diagnosis ( II v  III) and the
extent of residual disease after cytoreductive surgery (no residual disease v
presence of residual disease).
RESULTS
Patient Characteristics
In total, 844 patients consented and initiated screening. Of these,
142 patients were excluded as a result of ineligible histologic diagnosis
at review or for logistic reasons, and 702 patients were randomly
assigned (345 were assigned to active treatment and 357 were assigned
to standard care). After random assignment, 133 patients were ex-
cluded as a result of reasons listed in Table 1, 122 patients were found
to have residual disease at SLL. The remaining 447 patients constituted
the intent-to-treat analysis group (224 patients in the active treatment
group and 223 in the standard care group). The median duration of
follow-up was 1,042 days. In total, 296 patients completed the study
(145 patients in the active treatment group and 151 in the standard
care group), 131 patients died (70 patients in the active group and 61 in
the standard care group), eight patients withdrew consent (two pa-
tients in the active group and six patients in the standard care group),
seven patients were withdrawn for other reasons (four patients in the
active treatment group and three in the standard care group), and five
patients were lost to follow-up (three patients in the active treatment
group and two in the standard care group).
Baseline patient demographics and disease characteristics are
listed in Table 2. Overall, patient characteristics at baseline were well
balanced between the two treatment arms, although there was a higher
proportion of patients in the 90Y-muHMFG1 arm with residual dis-
ease after their primary surgery compared with the standard care arm
(44.2% v 35.9%, respectively). As part of the random assignment
process, residual disease was included as a covariate in the analysis.
The median age of patients in the active treatment and standard
care arms was 54.5 and 53.7 years, respectively. The majority of pa-
tients were FIGO stage III or greater at baseline (72.3% in the 90Y-
muHMFG1 arm and 69.5% in the standard care arm). The most
common histologic tumor subtype in both arms was serous (64.1%
in the 90Y-muHMFG1 arm and 57.5% in the standard care arm).
Fifty-seven percent of patients in the 90Y-muHMFG1 arm and
55.7% of patients in the standard care arm had poorly differenti-
ated tumor types.
During the follow-up period, 58.0% of patients in the 90Y-
muHMFG1 group and 55.6% of patients in the standard care group
Table 1. Screening Failures: Reasons Why Patients Were Excluded
From the Study After Second-Look Laparoscopy Was Performed
(ie, before the random assignment code was broken)
Reason
Experimental
Arm (No.)
Standard Arm
(No.)
Total
(No.)
HAMA positive 6 17 23
Histology failure on review 6 9 15
Residual disease on CT or biopsy 6 4 10
Raised CA-125 3 4 7
Medical problems 5 3 8
Myelosuppression 3 4 7
Patient withdrawal 3 6 9
Doctor/sponsor withdrawal 1 3 4
Adhesions at laparoscopy 17 14 31
Laparoscopic complications 4 2 6
Poor distribution on imaging study 6 0 6
Other 1 6 7
Total 61 72 133
Abbreviations: HAMA, human antimurine antibodies; CT, computed tomography.
Table 2. Patient Demographics and Disease Characteristics
Demographic/Characteristic
% of Patients
90Y-muHMFG1 Standard Care
Age, years
Median 54.5 53.7
Range 21-76 23-79
ECOG performance status
0 77.6 75.0
1-2 22.4 25.0
FIGO stage
Ic 14.3 16.1
IIa 2.2 4.0
IIb 3.6 2.2
IIc 7.6 8.1
III 66.1 64.1
IV 6.3 5.4
Histology
Serous 64.1 57.5
Mucinous 2.3 6.3
Endometrioid 25.0 22.6
Clear cell 10.0 12.2
Malignant Brenner 0.5 0.5
Undifferentiated 4.5 5.0
Other 2.3 3.2
MUC1-stained cells
 60% 18.4 23.6
 60% 81.6 76.4
Prior taxane 92.4 93.3
Residual disease after surgery
Yes 44.2 35.9
No 47.8 55.2
Unknown 8.0 9.0
Microscopic disease at SLL
Yes 9.8 10.3
No 90.2 89.7
Abbreviations: 90Y-muHMFG1, yttrium-90-labeled muHMFG1; ECOG, East-
ern Cooperative Oncology Group; FIGO, International Federation of Gynecol-
ogy and Obstetrics; SLL, second-look laparoscopy.
Trial of Radiolabeled HMFG1 in Ovarian Cancer
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received chemotherapy. Within 100 days of laparoscopy, 12.5% of
patients in the 90Y-muHMFG1 group and 19.7% in the standard care
group received chemotherapy. The most commonly used second-line
chemotherapeutic regimens were platinum/taxane/other (31.5% in
the 90Y-muHMFG1 arm and 36.3% in the standard care arm) and
platinum/other (23.8% in the 90Y-muHMFG1 arm and 23.4% on the
standard care arm).
Efficacy
The primary efficacy end point was length of survival. A Kaplan-
Meier plot of survival times is shown in Figure 1. Cox proportional
hazards model analysis of survival showed no significant difference in
survival times between the 90Y-muHMFG1 arm and the standard care
arm, with a relative risk of death of 1.159 (P  .4033). During the
study, 70 patients (31.3%) died on the 90Y-muHMFG1 arm, and 61
(27.4%) died on the standard care arm. An exploratory analysis of
subgroups failed to identify a subgroup that benefited from 90Y-
muHMFG1 treatment compared with the standard care arm. Sub-
group analyses comprised FIGO stage, presence or absence of
microscopic disease at SLL, presence or absence of residual disease
after primary surgery, histology (serous or other), number of MUC1-
stained cells ( 60% or  60%), intensity of stained cells, level of
differentiation (well/moderate or poor), age (55 or55 years), and
location (United States or non–United States).
A multivariate analysis was performed to look at the impact of
baseline disease characteristics on survival for the entire study popu-
lation (Table 3). The relative risk of death was significantly greater for
patients with a FIGO stage of III at baseline compared with patients
with a FIGO stage of II (relative risk 2.733; P .0003). Patients
with microscopic disease at the time of the SLL had a significantly
higher relative risk of death compared with patients without micro-
scopic disease (relative risk 1.81; P .0125).
Figure 2 is a Kaplan-Meier plot of time to relapse. There was no
statistically significant difference between the 90Y-muHMFG1 arm
and the standard care arm with respect to time to relapse (relative
risk 0.904; P .4764). There were 104 relapses (46.4%) on the
90Y-muHMFG1 arm and 98 relapses (43.9%) on the standard care
arm. Multivariate analysis looking at the impact of baseline char-
acteristics on relapse demonstrated that patients whose disease was
FIGO stage III or greater at baseline were at significantly greater
risk of relapse than patients whose disease was FIGO stage II or less
(relative risk  3.126; P  .0001; Table 4). Additionally, patients
with residual disease after primary surgery were at significantly greater
risk of relapse than patients without residual disease (relative risk
1.432; P .0241).
Mean CA-125 levels after laparoscopy initially increased for the
experimental arm compared with the standard care arm; however, by
month 3, CA-125 levels were similar in both treatment arms. There
was no statistically significant difference in the time to serologic re-
lapse in the 90Y-muHMFG1 arm compared with the standard care
arm, with a relative risk of serologic relapse of 0.83 (P  .3140).
Multivariate analysis of the effect of baseline factors on serologic
relapse showed also that the relative risk of serologic relapse was
significantly greater for patients with FIGO stage III or greater disease
at baseline compared with patients with FIGO stage II or less disease
(relative risk  4.427; P  .0001). Similarly, patients with residual
disease after primary surgery had a significantly greater risk of sero-
logic relapse than patients without residual disease (relative risk 
1.535; P .0381).
Safety
Adverse events were collected during the first 90 days of the study.
The most common clinical adverse events are listed in Table 5. The
most common events associated with 90Y-muHMFG1 treatment were
nausea, fatigue, arthralgia, myalgia, abdominal pain, rash, vomiting,
and diarrhea. These events were predominantly mild to moderate in
severity and were transient.
Hematologic toxicities were more common in the 90Y-muHMFG1
arm compared with the standard care arm, with the peak incidence
occurring approximately 6 weeks after study medication adminis-
tration (Table 6). By week 8, more than 80% of patients who received
90Y-muHMFG1 had at least one hematologic toxicity, and 26% of
patients had National Cancer Institute grade 3 or 4 hematologic
toxicities. Thrombocytopenia was the most common hematologic
Fig 1. Kaplan-Meier curve of survival (intent-to-treat population). 90Y-
muHMFG1, yttrium-90–labeled murine HMFG1.
Table 3. Disease, Treatment, and Patient Characteristics Evaluated for an Association With Disease Recurrence: Cox Regression Analysis
of Time to Death (intent-to-treat population)
Characteristic Relative Risk 95% CI Z P
90Y-muHMFG1 v standard care 1.159 0.82 to 1.636 0.835 .4034
FIGO stage  III v  II 2.733 1.58 to 4.727 3.598 .0003
Residual disease, yes v no 1.305 0.879 to 1.938 1.321 .1866
Residual disease, not known v no 1.899 1.045 to 3.452 2.105 .0353
Microscopic disease at SLL, no v yes 0.551 0.345 to 0.879 2.499 .0125
Abbreviations: 90Y-muHMFG1, yttrium-90-labeled muHMFG1; FIGO, International Federation of Gynecology and Obstetrics; SLL, second-look laparoscopy.
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toxicity associated with 90Y-muHMFG1 and was recorded for
24.3% of patients. Serious adverse events were balanced between
the two arms, and most were attributed to complications of recur-
rent disease.
DISCUSSION
Although more radical surgical technologies exist and better chemo-
therapeutic regimens have significantly improved the interval between
diagnosis and death, the overall survival rate for advanced cancer of
the ovary has not changed significantly over the last 25 years. A single
IP administration of 90Y-muHMFG1 murine monoclonal antibody
did not prolong survival in patients with a negative SLL after surgical
debulking and platinum-based chemotherapy. Moreover, the propor-
tion of patients with tumor recurrence and the time to relapse were
similar in the two treatment arms. No subgroup of patients could be
identified for whom IP radiolabeled antibody conferred an advantage
compared with standard care. At the time of analysis, the study was
adequately powered to detect a 15% difference in survival, if such a
difference existed. The group randomly assigned to 90Y-muHMFG1
did not show an increase in severe adverse events. Baseline factors
found to have a detrimental effect on mortality were higher FIGO
stage, presence of residual disease after primary surgery, presence of
microscopic disease at SLL, and poorly differentiated tumor types.
This is the largest prospective and randomized trial evaluating a
novel therapeutic strategy in women with no evidence of macroscopic
disease at SLL after primary platinum-based therapy. Prior studies
using IP platinum, oral hexamethylmelamine, or even high-dose che-
motherapy with autologous bone marrow or stem-cell rescue have
also explored consolidation or intensification strategies.16 All of these
trials have demonstrated that these therapies are feasible in selected
patient populations, with encouraging disease-free survival in phase II
studies. For example, administration of 6 months of oral hexamethyl-
melamine to a group of women in a clinical complete response led to
a 28-month disease-free survival.17 Administration of IP platinum to a
group of women with a negative second-look laparotomy was also
associated with a long disease-free period.18 All of these trials were
single armed and, hence, cannot exclude selection bias. The recently
reported Southwest Oncology Group/Gynecologic Oncology Group
study was a randomized comparison of short-course (3-month) pac-
litaxel versus a year of paclitaxel consolidation. This study demon-
strated a significant prolongation in disease-free survival, but its
design did not allow demonstration of a survival advantage.19 A report
of a randomized trial evaluating consolidation therapy in women who
had a response to primary platinum-based therapy demonstrated that
consolidating topotecan offered no advantage to immediate chemo-
therapy.20 In the majority of these studies, response was clinically
defined instead of surgically determined.
Why did this study fail to demonstrate an effect on disease-free or
overall survival? In retrospect, dose and pharmacokinetics, as well as
biologic factors, may have reduced the likelihood of success. The dose
of the radionuclide may have been insufficient. In previous studies, we
attempted to estimate the microdosimetry to the peritoneal surface
after IP administration of radiolabeled antibodies such as HMFG1. It
was found that, when using iodine-131 as the radiolabel, the dose of
radiation from a single administration of radiolabeled antibody was
sufficiently high to sterilize macroscopic epithelial tumors, such as
ovarian cancer, in only a few patients.21 Therefore, the isotope was
changed from iodine-131 to yttrium-90 with the expectation that
dosimetry would be more favorable.22 It is conceivable that substitu-
tion of yttrium with lutetium or rhenium would have further im-
proved efficacy, but these radionuclides were not in clinical use at the
time of study initiation. Although 80% of the antibody was unlabeled,
previous studies had supported this mixture to optimize pharmacoki-
netics.15 Finally, in contrast to previous studies, our patients all had
microscopic residual disease at most, which may theoretically have
hampered sufficient or appropriate binding.
Pharmacokinetics were not performed in this study, and it is
possible that there was limited systemic exposure to the intact radio-
immunoconjugate. From previous studies, it was known that ap-
proximately 20% of the injected dose could enter the systemic
circulation within 48 hours from the time of administration. There
is growing evidence that EOC is a systemic disease, and although
the bulk of this tumor resides within the peritoneal cavity, tumor
Fig 2. Kaplan-Meier curve of time to relapse (intent-to-treat population).
90Y-muHMFG1, yttrium-90–labeled murine HMFG1.
Table 4. Disease, Treatment, and Patient Characteristics Evaluated for an Association With Disease Recurrence: Cox Regression Analysis
of Time to Relapse (intent-to-treat population)
Characteristic Relative Risk 95% CI Z P
90Y-muHMFG1 v standard care 0.904 0.685 to 1.194 0.71 .4776
FIGO stage  III v  II 3.126 2.054 to 4.758 5.319 .0000
Residual disease, yes v no 1.432 1.048 to 1.957 2.255 .0241
Residual disease, not known v no 1.331 0.779 to 2.273 1.047 .2950
Abbreviations: 90Y-muHMFG1, yttrium-90-labeled muHMFG1; FIGO, International Federation of Gynecology and Obstetrics.
Trial of Radiolabeled HMFG1 in Ovarian Cancer
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cells can frequently be detected in retroperitoneal lymph nodes,
bone marrow, and blood at the time of diagnosis. Limited extra-
peritoneal exposure with this agent may be a contributory factor to
the failure of the current approach.
Limited radiation dose to the tumor from a single administration
of 90Y-muHMFG1 may be the most important reason why this ap-
proach failed. This may be overcome by repeat doses of radiolabeled
antibody preferably using a nonimmunogenic protein, such as human
or humanized antibody, administered concurrently with, rather than
after, chemotherapy, as was done in this study. It has recently been
shown by several investigators that one can obtain a cooperative effect
when radiolabeled antibodies are combined with chemotherapy.23
Several issues precluded such a study design, including concerns about
cumulative hematologic toxicity and logistic challenges of repetitive
administration of IP radiolabeled antibody and the development of
HAMA. This latter issue may not be a significant limitation with IP
administration because the IP-administered antibody enters the sys-
temic circulation slowly.
Biologic issues may have also limited the trial’s chance for suc-
cess, including the submesothelial location of tumor metastases that
may have shielded the MUC1 antigen expression from the IP cavity,
thus avoiding interaction with the antimucin antibody. It is also pos-
sible that nests of residual small-volume disease include clusters of
cells that lack the appropriate mucin epitope. However, the beta radi-
ation emitted from the yttrium-90 isotope should be able to reach and
irradiate clusters of antigen-negative tumor cells that are present a few
millimeters away from the tumor-bound radiolabeled antibody. It is
possible that delivery of this therapy immediately postoperatively or
further from primary therapy may have provided more optimal phys-
iologic or immunologic conditions for success.
Another potentially confounding variable was the use of ad-
ditional consolidation strategies in both the active and control
populations. The publication of the Southwest Oncology Group/
Gynecologic Oncology Group paclitaxel consolidation study, as
well as institutional and/or investigator biases about the potential
value of consolidation, required the incorporation of such treat-
ment at the discretion of the lead investigators. The use of consol-
idation was to be defined by the institution’s lead investigator at the
time the trial was opened, and both the control and active treat-
ment arms were to receive this therapy. Most institutions did not
incorporate consolidation strategies, whereas other institutions
did incorporate paclitaxel or other therapies. Within 100 days of
laparoscopy, 19.7% of patients randomly assigned to standard care
received chemotherapy, which, in view of the timing, should be re-
garded as consolidation therapy, compared with 12.5% of patients
assigned to the 90Y-muHMFG1 arm. It is possible that the unbalanced
delivery of consolidation therapy may have altered the study outcome
or, alternatively, that such therapies abrogated the potential benefit of
what might be considered an IP immunotherapy.
Despite the lack of therapeutic efficacy, this study has provided
the largest prospectively collected database of patients with a negative
SLL and is, therefore, a valuable resource for studying patients with
EOC who respond well to primary therapy. For example, the database
can be used to study the impact of various prognostic factors in this
patient population, predictors of negative SLL, safety of SLL in this
patient population, and patterns of relapse in both the treated and
untreated population. Such analyses, although not part of the primary
study design, are currently being undertaken.
This study constitutes the largest prospective series of laparos-
copy after primary treatment for ovarian cancer. In a comparative but
small (20 patients) study of SLL versus second-look laparotomy,
Clough et al24 were unable to perform a complete IP investigation in
59% of laparoscopies compared with 5% of laparotomies. Our study
refutes these results and indicates that laparoscopy is a safe and ade-
quate procedure in patients who have undergone extensive primary
surgical as well as cytostatic treatment. Specifically, our findings con-
firm that, after chemotherapy, adhesions usually do not hamper IP
administration. Moreover, chemotherapy might even diminish adhe-
sion formation.25
Table 6. National Cancer Institute Grade 3 or 4 Hematologic Toxicity at
Weeks 0, 4, 6, and 8 and Month 6 for the Experimental Arm
Time
Platelets Neutrophils
Grade  3 Grade  3
No. of Patients % No. of Patients %
Week 0 0 0 0 0
Week 4 9 4.3 0 0
Week 6 51 24.3 1 0.5
Week 8 27 12.9 1 0.5
Month 6 5 2.4 0 0
Table 5. Common Adverse Events by National Cancer Institute Grade
Adverse Event
90Y-muHMFG1
(n  224)
Standard Care
(n  223)
Mild Moderate Severe Mild Moderate Severe
No. % No. % No. % No. % No. % No. %
Nausea 60 27 28 13 6 3 29 13 14 6 3 1
Fatigue 49 22 27 12 2  1 28 13 18 8 1  1
Arthralgia 46 21 22 10 6 3 24 11 17 8 0 0
Myalgia 35 16 20 9 4 2 9 4 6 3 0 0
Abdominal pain 37 17 19 8 5 2 21 9 16 7 7 3
Rash 29 13 10 4 1  1 6 3 5 2 2  1
Diarrhea 24 11 13 6 0 0 12 5 6 3 2  1
Vomiting 23 10 16 7 2  1 14 6 5 2 2  1
Abbreviation: 90Y-muHMFG1, yttrium-90-labeled muHMFG1.
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This study reaffirms the need for randomized trials in this clinical
setting. Strategies to target and eliminate small-volume residual dis-
ease at the conclusion of primary chemotherapy remain a high priority
in this disease. New targeted therapies, immunotherapies, and chemo-
therapeutic agents with novel mechanisms of action may offer benefit
and should be considered for testing in a similar setting. Hopefully,
information gleaned from the conduct of this study will aid in the
execution of those trials.
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